Jose I Emparanza1, Adolfo López de Munain2, Mark H Greene3, Ander Matheu4, Roberto Fernández-Torrón2, Shahinaz M Gadalla3. 1. Clinical Epidemiology Unit, Donostia University Hospital, San Sebastian, Spain. 2. Department of Neurology, Donostia University Hospital, San Sebastian, Spain. 3. Clinical Genetics Branch, National Cancer Institute, Bethesda, Maryland, USA. 4. Oncology Area, Institute Biodonostia, San Sebastián, Spain.
Abstract
INTRODUCTION: Recent studies have provided evidence that patients with myotonic dystrophy (DM) are at excess risk of cancer. However, inconsistencies regarding affected anatomic sites persist. METHODS: We performed a meta-analysis of cancer risk in DM, searching among studies published between January 1, 1990 and December 31, 2016. Eligible studies were full reports of DM cohorts with site-specific risks. RESULTS: The analysis included 5 studies, comprising 2,779 patients. Risk estimates for cancers of the endometrium and cutaneous melanoma were reported in all studies. The pooled standardized incidence ratio (pSIRs) for endometrial cancer was 7.48 (95% confidence interval [CI] 4.72-11.8) and for cutaneous melanoma was 2.45 (95% CI 1.31-4.58). Among cancers reported in 4 of 5 studies, elevated risks were observed for thyroid (pSIR = 8.52, 95% CI 3.62-20.1), ovarian (pSIR = 5.56, 95% CI 2.99-10.3), testicular (pSIR = 5.95, 95% CI 2.34-15.1), and colorectal (pSIR = 2.2, 95% CI 1.39-3.49) cancers. DISCUSSION: Our data refine the DM cancer phenotype, which may guide patient clinical management and inform plans for molecular investigations to understand DM-related carcinogenesis. Muscle Nerve 58: 517-522, 2018.
INTRODUCTION: Recent studies have provided evidence that patients with myotonic dystrophy (DM) are at excess risk of cancer. However, inconsistencies regarding affected anatomic sites persist. METHODS: We performed a meta-analysis of cancer risk in DM, searching among studies published between January 1, 1990 and December 31, 2016. Eligible studies were full reports of DM cohorts with site-specific risks. RESULTS: The analysis included 5 studies, comprising 2,779 patients. Risk estimates for cancers of the endometrium and cutaneous melanoma were reported in all studies. The pooled standardized incidence ratio (pSIRs) for endometrial cancer was 7.48 (95% confidence interval [CI] 4.72-11.8) and for cutaneous melanoma was 2.45 (95% CI 1.31-4.58). Among cancers reported in 4 of 5 studies, elevated risks were observed for thyroid (pSIR = 8.52, 95% CI 3.62-20.1), ovarian (pSIR = 5.56, 95% CI 2.99-10.3), testicular (pSIR = 5.95, 95% CI 2.34-15.1), and colorectal (pSIR = 2.2, 95% CI 1.39-3.49) cancers. DISCUSSION: Our data refine the DM cancer phenotype, which may guide patient clinical management and inform plans for molecular investigations to understand DM-related carcinogenesis. Muscle Nerve 58: 517-522, 2018.
Authors: Shahinaz M Gadalla; Marie Lund; Ruth M Pfeiffer; Sanne Gørtz; Christine M Mueller; Richard T Moxley; Sigurdur Y Kristinsson; Magnus Björkholm; Fatma M Shebl; James E Hilbert; Ola Landgren; Jan Wohlfahrt; Mads Melbye; Mark H Greene Journal: JAMA Date: 2011-12-14 Impact factor: 56.272
Authors: Maya Das; Richard T Moxley; James E Hilbert; William B Martens; Lisa Letren; Mark H Greene; Shahinaz M Gadalla Journal: J Neurol Date: 2012-05-23 Impact factor: 4.849
Authors: Hongqing Du; Melissa S Cline; Robert J Osborne; Daniel L Tuttle; Tyson A Clark; John Paul Donohue; Megan P Hall; Lily Shiue; Maurice S Swanson; Charles A Thornton; Manuel Ares Journal: Nat Struct Mol Biol Date: 2010-01-24 Impact factor: 15.369
Authors: Christine M Mueller; James E Hilbert; William Martens; Charles A Thornton; Richard T Moxley; Mark H Greene Journal: Cancer Causes Control Date: 2009-12 Impact factor: 2.506
Authors: J D Brook; M E McCurrach; H G Harley; A J Buckler; D Church; H Aburatani; K Hunter; V P Stanton; J P Thirion; T Hudson Journal: Cell Date: 1992-02-21 Impact factor: 41.582
Authors: Alba Judith Mateos-Aierdi; Maria Goicoechea; Ana Aiastui; Roberto Fernández-Torrón; Mikel Garcia-Puga; Ander Matheu; Adolfo López de Munain Journal: Front Aging Neurosci Date: 2015-07-09 Impact factor: 5.750
Authors: Shahinaz M Gadalla; Ruth M Pfeiffer; Sigurdur Y Kristinsson; Magnus Björkholm; James E Hilbert; Richard T Moxley; Ola Landgren; Mark H Greene Journal: PLoS One Date: 2013-11-13 Impact factor: 3.240
Authors: Cecilia Higgs; James E Hilbert; Libby Wood; William B Martens; Chiara Marini-Bettolo; Nikoletta Nikolenko; Rotana Alsaggaf; Hanns Lochmüller; Richard T Moxley; Mark H Greene; Youjin Wang; Shahinaz M Gadalla Journal: Front Neurol Date: 2019-10-11 Impact factor: 4.003
Authors: Rotana Alsaggaf; Diane Marie M St George; Min Zhan; Ruth M Pfeiffer; Youjin Wang; Lesley A Anderson; Zhiwei Liu; Jill Koshiol; Andrew J Bauer; Kathryn R Wagner; Mark H Greene; Sania Amr; Shahinaz M Gadalla Journal: Ann Clin Transl Neurol Date: 2019-07-26 Impact factor: 4.511
Authors: Rotana Alsaggaf; Ruth M Pfeiffer; Youjin Wang; Diane Marie M St George; Min Zhan; Kathryn R Wagner; Sania Amr; Mark H Greene; Shahinaz M Gadalla Journal: Int J Cancer Date: 2019-12-19 Impact factor: 7.316
Authors: Łukasz J Sznajder; Marina M Scotti; Jihae Shin; Katarzyna Taylor; Franjo Ivankovic; Curtis A Nutter; Faaiq N Aslam; S H Subramony; Laura P W Ranum; Maurice S Swanson Journal: Nat Commun Date: 2020-04-24 Impact factor: 14.919